IDEXX Laboratories, Inc. (NASDAQ:IDXX) Position Increased by SRS Capital Advisors Inc.

SRS Capital Advisors Inc. raised its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 363.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 366 shares of the company’s stock after buying an additional 287 shares during the period. SRS Capital Advisors Inc.’s holdings in IDEXX Laboratories were worth $151,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. FSA Wealth Management LLC purchased a new position in shares of IDEXX Laboratories in the third quarter worth approximately $25,000. Ashton Thomas Securities LLC purchased a new stake in IDEXX Laboratories in the 3rd quarter worth about $37,000. Retirement Wealth Solutions LLC acquired a new stake in IDEXX Laboratories during the 4th quarter worth about $31,000. Kestra Investment Management LLC acquired a new stake in shares of IDEXX Laboratories during the fourth quarter worth approximately $38,000. Finally, Crews Bank & Trust purchased a new position in IDEXX Laboratories during the fourth quarter valued at approximately $41,000. 87.84% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

IDXX has been the subject of several recent research reports. StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday, February 27th. Barclays increased their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Bank of America boosted their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. Leerink Partners began coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price for the company. Finally, Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $533.75.

IDEXX Laboratories Trading Down 1.0 %

Shares of IDXX stock opened at $437.23 on Thursday. The company has a market capitalization of $35.56 billion, a P/E ratio of 40.98, a P/E/G ratio of 3.41 and a beta of 1.37. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $574.94. The firm has a 50-day moving average price of $436.83 and a 200 day moving average price of $450.33. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.11% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.